Association of Helicobacter Pylori DupA with the Failure of Primary Eradication

Overview

Journal J Clin Gastroenterol

Specialty Gastroenterology

Date 2012 Feb 3

PMID 22298090

Citations 19

Authors

Seiji Shiota

Lam Tung Nguyen

Kazunari Murakami

Akiko Kuroda

Kazuhiro Mizukami

Tadayoshi Okimoto

Masaaki Kodama

Toshio Fujioka

Yoshio Yamaoka

Affiliations

Soon will be listed here.

Abstract

Goals: To determine whether the presence of dupA Helicobacter pylori (H. pylori) influences the cure rate of primary eradication therapy.

Background: Several virulence factors of H. pylori have been reported to affect the efficacy of the eradication rate. However, no study has investigated whether the presence of dupA affects eradication failure.

Study: The presence of dupA was evaluated in 142 H. pylori strains isolated from 142 patients with gastrointestinal diseases. Of these patients, 104 received primary eradication therapy for 1 week. The risk factors for eradication failure were determined using univariate and multivariate analyses.

Results: Among 142 strains, 44 (31.0%) were dupA positive. There was no association between dupA status and gastroduodenal diseases (P>0.05). The clarithromycin (CLR) resistance rate was generally lower in the dupA-positive than in the dupA-negative group (20.4% vs. 35.7%, P=0.06). However, dupA prevalence was higher in the eradication failure group than in the success group (36.3% vs. 21.9%). Among the CLR-resistant H. pylori infected group, the successful eradication rate was significantly lower in patients infected with dupA-positive H. pylori than dupA-negative H. pylori (P=0.04). In multivariate analysis adjusted for age, sex, and type of disease, not only CLR resistance but also dupA presence was independent risk factors for eradication failure (adjusted odds ratio=3.71; 95% confidence interval,1.07-12.83).

Conclusions: Although CLR resistant was more reliable predictor, the presence of dupA may also be an independent risk factor for eradication failure.

Citing Articles

Exploring virulence factors of Helicobacter pylori isolated from gastric biopsy.

Javanbakhat P, Peeridogaheh H, Nemati R, Yazdanbod A, Teimourpour A, Sadeghnezhad M Mol Biol Rep. 2024; 51(1):192.

PMID: 38270789 DOI: 10.1007/s11033-023-09075-z.

Biomarker Characterization and Prediction of Virulence and Antibiotic Resistance from Next Generation Sequencing Data.

Vital J, Tanoeiro L, Lopes-Oliveira R, Vale F Biomolecules. 2022; 12(5).

PMID: 35625618 PMC: 9138241. DOI: 10.3390/biom12050691.

Influence of Genotype on Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis.

Morino Y, Sugimoto M, Nagata N, Niikiura R, Iwata E, Hamada M Front Pharmacol. 2021; 12:759249.

PMID: 34721043 PMC: 8553963. DOI: 10.3389/fphar.2021.759249.

Virulence Factors-Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment.

Baj J, Forma A, Sitarz M, Portincasa P, Garruti G, Krasowska D Cells. 2020; 10(1).

PMID: 33375694 PMC: 7824444. DOI: 10.3390/cells10010027.

Investigation of Clarithromycin Resistance-Associated Mutations and Virulence Genotypes of Helicobacter pylori Isolated from Iranian Population: A Cross-Sectional Study.

Alavifard H, Mirzaei N, Yadegar A, Baghaei K, Smith S, Sadeghi A Curr Microbiol. 2020; 78(1):244-254.

PMID: 33251569 DOI: 10.1007/s00284-020-02295-7.

References

PETERSON W . The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997; 11 Suppl 1:21-5. DOI: 10.1046/j.1365-2036.11.s1.4.x. View

Sugimoto M, Yamaoka Y . Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch Immunol Ther Exp (Warsz). 2009; 57(1):45-56. PMC: 3118989. DOI: 10.1007/s00005-009-0007-z. View

Hunt R . pH and Hp--gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol. 1993; 88(4):481-3. View

De Francesco V, Zullo A, Margiotta M, Marangi S, Burattini O, Berloco P . Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther. 2004; 19(4):407-14. DOI: 10.1046/j.1365-2036.2004.01818.x. View

Shiota S, Matsunari O, Watada M, Hanada K, Yamaoka Y . Systematic review and meta-analysis: the relationship between the Helicobacter pylori dupA gene and clinical outcomes. Gut Pathog. 2010; 2(1):13. PMC: 2988691. DOI: 10.1186/1757-4749-2-13. View

Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H . Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010; 15(1):1-20. DOI: 10.1111/j.1523-5378.2009.00738.x. View

Maeda S, Yoshida H, Ikenoue T, Ogura K, Kanai F, Kato N . Structure of cag pathogenicity island in Japanese Helicobacter pylori isolates. Gut. 1999; 44(3):336-41. PMC: 1727424. DOI: 10.1136/gut.44.3.336. View

Nguyen L, Uchida T, Tsukamoto Y, Kuroda A, Okimoto T, Kodama M . Helicobacter pylori dupA gene is not associated with clinical outcomes in the Japanese population. Clin Microbiol Infect. 2009; 16(8):1264-9. DOI: 10.1111/j.1469-0691.2009.03081.x. View

De Francesco V, Margiotta M, Zullo A, Hassan C, Della Valle N, Burattini O . Claritromycin resistance and Helicobacter pylori genotypes in Italy. J Microbiol. 2007; 44(6):660-4. View

10.

Elviss N, Owen R, Xerry J, Walker A, Davies K . Helicobacter pylori antibiotic resistance patterns and genotypes in adult dyspeptic patients from a regional population in North Wales. J Antimicrob Chemother. 2004; 54(2):435-40. DOI: 10.1093/jac/dkh343. View

11.

van der Hulst R, van der Ende A, Dekker F, Ten Kate F, Weel J, Keller J . Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology. 1997; 113(1):25-30. DOI: 10.1016/s0016-5085(97)70076-3. View

12.

Grayson M, Eliopoulos G, Ferraro M, Moellering Jr R . Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1989; 8(10):888-9. DOI: 10.1007/BF01963775. View

13.

Yamaoka Y . Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol. 2010; 7(11):629-41. PMC: 3137895. DOI: 10.1038/nrgastro.2010.154. View

14.

Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M . Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother. 2007; 8(16):2701-17. DOI: 10.1517/14656566.8.16.2701. View

15.

Humphries R, Bobenchik A, Hindler J, Schuetz A . Overview of Changes to the Clinical and Laboratory Standards Institute M100, 31st Edition. J Clin Microbiol. 2021; 59(12):e0021321. PMC: 8601225. DOI: 10.1128/JCM.00213-21. View

16.

Lu H, Hsu P, Graham D, Yamaoka Y . Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology. 2005; 128(4):833-48. PMC: 3130061. DOI: 10.1053/j.gastro.2005.01.009. View

17.

Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y . Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter. 2009; 14(5):86-90. DOI: 10.1111/j.1523-5378.2009.00714.x. View

18.

Suzuki T, Matsuo K, Sawaki A, Ito H, Hirose K, Wakai K . Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2006; 24(2):273-80. DOI: 10.1111/j.1365-2036.2006.02994.x. View

19.

Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S . Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol. 2007; 45(12):4006-10. PMC: 2168569. DOI: 10.1128/JCM.00740-07. View

20.

Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K, Graham D . Relationship of vacA genotypes of Helicobacter pylori to cagA status, cytotoxin production, and clinical outcome. Helicobacter. 1998; 3(4):241-53. DOI: 10.1046/j.1523-5378.1998.08056.x. View